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Rationale: The Environmental Exposure Unit (EEU), a controlled allergen exposure model of allergic rhinitis (AR), has
traditionally utilized ragweed pollen. We sought to clinically validate the use of grass pollen in the EEU.
Methods: Healthy volunteers with a history of AR symptoms during grass pollen season and supportive skin test
responses attended the EEU for 3 hrs of rye grass pollen exposure (Lolium Perenne). Non-atopic controls were also
recruited. Participants assessed individual rhinoconjunctivitis symptoms to generate Total Nasal Symptom Score
(TNSS; max 12) and Total Symptom Score (TSS; max 24) and recorded Peak Nasal Inspiratory Flow (PNIF) q30min
while in the EEU. Participants returned the following day for an additional 3 hrs of pollen exposure. Two separate
groups allowed for the exploration of lower vs. higher pollen concentrations and subsequent effects on symptoms.
Results: 78 participants were screened, of whom 39 were eligible and attended the 2x3h EEU visits, plus 8 non-atopic
controls. Mean TSS, TNSS and PNIF values amongst participants in the higher pollen concentration group (target 3500
grains/m3) after the first 3 hr exposure were 18.9, 9.7 and 68 L/min, respectively. In comparison, mean TSS, TNSS and
PNIF values in the lower pollen concentration (2500 grains/m3) group were only 13.3, 7.6, and 82 L/min, respectively.
The subsequent day of pollen exposure did not appreciably alter the maximal TSS/TNSSs, but rather resulted in a more
rapid onset of symptomatology, with higher mean scores at the 30 min, 60 min and 90 min timepoints. The non-atopic
controls remained asymptomatic.
Conclusions: This study provides clinical validation of the ability to generate allergic rhinoconjunctivitis symptoms
amongst grass-allergic individuals in the EEU.
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A significant proportion of the North American popula-
tion suffers from the symptoms of seasonal allergic rhinitis
(SAR) [1]. The Environmental Exposure Unit (EEU), devel-
oped at Kingston General Hospital and Queen's University
in Kingston, Ontario, Canada, was the first such facility to
be developed in North America, and is an internationally
recognized and validated controlled allergen challenge
model of allergic rhinitis (AR). This specially designed
room provides a unique study environment ideally suited
to evaluate various pathophysiologic processes at work in* Correspondence: ellisa@kgh.kari.net
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unless otherwise stated.AR, as well as to assess the efficacy and onset of action of
various anti-allergic medications [2].
The EEU is a room measuring 21 × 15 m with a feeder
system that delivers controlled levels of commercially ob-
tained pollen into the seating area. Fans are organized to
continuously circulate the air in the room, and seven im-
pact type particle samplers (Rotorod® counters) are ar-
ranged to determine pollen levels throughout the room
every 30 minutes. This particular sampling technology has
been studied and shown to produce optimal pollen mea-
surements within a controlled allergen challenge facility
[3]. The pollen emission rate is modified based on these
counts to maintain pollen concentrations within a narrow
range. Thus, the EEU provides a closed environment inis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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trolled, and constant level of airborne pollen.
The EEU has proven effective in multiple studies evalu-
ating various aspects of seasonal allergic rhinitis and its
treatments [4-17]. Previous studies conducted in the EEU
using ragweed pollen have shown 3500 grains/m3 ± 500 to
be an optimal concentration to produce symptoms similar
to those experienced in the outdoor environment. All pre-
vious EEU clinical trials have utilized ragweed pollen as
the allergen of choice for dispersal, due to the frequency
of ragweed allergy in the local population. Many emerging
treatments for allergic rhinitis, however, are allergen spe-
cific (e.g. novel immunotherapeutics), therefore it was de-
sirable to expand the repertoire of pollen selection for use
in the EEU.
Each type of pollen has unique features; ragweed pollen
has a barbed, “spiky” appearance on surface analysis, while
grass pollen has a smooth, almost pearl-like surface
(Figure 1). The barbed surface area of the ragweed pollen
gives it a “sticky” characteristic, increasing the rate of coin-
cidence of pollen grains as experienced while viewing the
Rotorod ® air samples under the microscope. This coinci-
dence, or sticking-together, of pollen grains may also im-
prove the pollen’s ability to stay aloft during increased air
current velocities.
Grass pollen has a particle size of 30 to 39 microns (as
compared to 18 to 20 for ragweed), which could poten-
tially either hinder or increase its ability to be sus-
pended. With enough air current to overcome its size
and increased mass, the large surface area of the grass
pollen would allow it to be positively affected by the air
current’s ability to keep it aloft. This loftiness may also
promote the grass pollen’s ability to travel longer dis-
tances without “falling out” of the air stream. Essentially,A B
Ragweed Pollen 
(Ambrosia artemisiifolia) 
Figure 1 Microscopic representation of a typical ragweed pollen (A) a
surface with tiny spikes on its surface, compared with the smooth surface oboth pollens have characteristics which promote the
ability to keep the pollen grains suspended and hence,
the ability to maintain proper concentrations within the
EEU. Preliminary validation studies conducted in the
EEU while it was fully set up, but absent of human vol-
unteers, have confirmed our ability to release, disperse,
and maintain grass pollen concentrations in the EEU
utilizing the existing pollen dispersal technology [18].
In order to explore and determine the clinical validity
of grass pollen delivery in the EEU, two concentrations
of grass pollen were compared to evaluate the potential
impact these differences may have on symptom scoring:
3500 grains/m3 and 2500 grains/m3. This study aimed to
determine the optimal amount of grass pollen/m3 re-
quired to ensure participants experience allergic symp-
toms in the EEU similar to those they would experience
outdoors, and additionally to clinically validate the use
of grass pollen within the EEU. Of note, despite the
rapid increase in the development of several controlled
allergen challenge facilities (CACF) as a model of allergic
rhinitis, to date, no international standards have been
established for validation of such facilities.
Methods
This study protocol was reviewed and approved by
Queen’s University and Affiliated Teaching Hospitals
Research Ethics Board, and all participants gave written
informed consent prior to the initiation of any study re-
lated procedures.
Participants
Participants on file were approached to participate in the
current study. Eligible participants were males or fe-
males between the ages of 18 and 65 with a positive skinGrass Pollen 
(Dactylis glomerata) 
nd grass pollen (B) grain. Notably, ragweed pollen has a burr-like
f grass pollen.
Table 2 Symptom score definitions
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wheal diameter at least 3 mm larger than that produced
by the negative control—who were able and willing to
provide written informed consent. Females of childbear-
ing potential were required to use a medically acceptable
method of birth control or to be abstinent throughout
the study. Participants unable to adhere to the washout
periods for the medications listed in Table 1 prior to
screening or pollen exposure visits, as well as those who
were experiencing an upper respiratory tract infection
within one week of any of the visits, were excluded. Also
ineligible were participants with asthma requiring the
use of a short-acting beta agonist greater than twice a
week, and those with a history of any disease or disorder
that, in the judgement of the investigator, would impact
a participant’s safety or the results of the study. Partici-
pants with a known history of positive test results for
Hepatitis B, Hepatitis C, HIV or tuberculosis other than
what would be anticipated following vaccination, or cur-
rently receiving allergen specific immunotherapy injec-
tions were excluded.
Study design
Participants initially attended a screening visit where the
following procedures were conducted: vital signs, skin
testing to a panel of allergens (rye grass, timothy grass,
standardized grass mix, ragweed, birch, tree mix, dog,
cat, D. pteronyssius (dust mite), D. farinae (dust mite),
and Alternaria), height and weight, physical examination
including detailed nasal examination, and urine preg-
nancy testing (for women of childbearing potential only).
Eligible participants returned to the EEU for two
3 hour sessions of rye grass pollen (Lolium Perenne) ex-
posure occurring on subsequent days. Participants were
randomly divided into two groups, attending separate
two-day sessions in the EEU. The two groups were ex-
posed to different levels of target grass pollen concentra-
tion in the EEU, either a lower pollen concentration of
2500 ± 500 grains/m3 or a standard pollen concentration
of 3500 ± 500 grains/m3. Peripheral blood samples were
collected before and after the visit (results not reported
here), and participants were asked to record their symp-
toms on diary cards at the beginning of the session, and
every half-hour throughout the session. Symptoms includedTable 1 Medication washout periods
Medication class Washout period
Antihistamines 7 days
Intranasal or inhaled corticosteroids 14 days
Intranasal or inhaled cromolyn 14 days
Systemic corticosteroids or astemizole 30 days
Participants were required to adhere to these washout periods prior to
screening or pollen exposure visits.rhinnorhea, nasal congestion, sneezing, nasal itching, itchy/
watery eyes, red/burning eyes and itching of the ears/
palate/throat (refer to Table 2 for definitions). These cards
were scanned electronically. The individual rhinoconjunc-
tivitis symptom scores submitted on the diary cards were
tallied to create a Total Nasal Symptom Score and a Total
Symptom Score (max of 12 and 24 respectively, see
Table 2) for each participant. Additionally, participants
measured their Peak Nasal Inspiratory Flow (PNIF) using
the In-Check PNIF meter (Clement Clark International) at
baseline and every 30 minutes during pollen exposure.
Participants remained in the EEU for the duration of the
3 hour pollen exposure period unless, in the judgement of
the investigator, symptoms became so intolerable that re-
moval from the EEU was warranted. Upon leaving the re-
search centre, participants were provided with a package
of diary cards in order to continue recording their symp-
toms and PNIF on an hourly basis, until 12 hours had
passed since the onset of the pollen exposure.
The next day, participants returned to the EEU for the
second of the two 3 hour sessions of grass pollen expos-
ure, and again recorded their symptom scores and PNIF
measurements every 30 minutes. The purpose of this
second day visit was to investigate the potential for any
priming of responses on Day 2 compared to Day 1, and
to evaluate tolerability of two “back to back” exposures.EEU methodology
As described above, the Kingston EEU is a specifically engi-
neered room located within Kingston General Hospital.
The EEU setup, including location of chairs, feeder, fans,
and Rotorod® sampling equipment, is illustrated in Figure 2.
A custom engineered computer and laser-aided system dis-
perses pollen, at a single point of delivery (Figure 2). The
pollen is propelled, by selectively placed groups of direc-
tional fans, over the participant seating area. For the
current study, rye grass pollen was sourced from Greer
Laboratories (Lenoir, NC), and was independently tested
for fungal and bacterial contamination (Paracel Laboratories,
Ottawa, ON, Canada) prior to its use.Rating Definition
0 = None Symptom is completely absent
1 = Mild Symptom is present, but not bothersome
2 = Moderate Symptom is bothersome, but tolerable
3 = Severe Symptom is hard to tolerate, desiring treatment
Participants used this rating system to score their symptoms of rhinnorhea,
nasal congestion, sneezing, nasal itching, itchy/watery eyes, red/burning eyes,
and itching of the ears/palate/throat. The individual symptom scores were
tallied to create a Total Nasal Symptom Score (max 12) and a Total Symptom
Score (max 24) for each participant.
Figure 2 Layout of the Environmental Exposure Unit (EEU).
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In order to discern correlations between reported mea-
sures of nasal congestion, TNSS, and PNIF for each par-
ticipant, Pearson’s correlation tests were conducted. The
statistical software GraphPad Prism 6 (GraphPad Software,
Inc) was used.
Results
78 potentially grass-allergic participants were screened,
of whom 39 were eligible and attended the 2 × 3 hour
EEU visits. 20 grass-allergic people attended the visits
with the higher pollen concentration and 19 were in the
lower target pollen concentration group. Following
screening, 8 eligible non-atopic controls were similarly
enrolled. The non-atopic controls remained asymptom-
atic throughout both days of pollen exposure in both
groups.
Total Symptom Score (TSS) and Total Nasal Symptom
Scores (TNSS)
Mean TSS and TNSS scores obtained in both the higher
(target 3500 grains/m3) and lower (2500 grains/m3)pollen concentration groups over both days of exposure
are summarized in Figures 3 and 4. Mean TSS and
TNSS amongst allergic participants in the higher pollen
concentration group after the first 3 hr exposure (i.e. at
hour 3) were 18.9 (SD = 2.7) and 9.7 (SD = 5.1), respect-
ively. In comparison, mean TSS and TNSS values in the
lower pollen concentration group were only 13.3 (SD =
5.9) and 7.6 (SD = 2.6), respectively.
The subsequent day of pollen exposure did not appre-
ciably alter the maximal TSS/TNSSs in either group, but
rather resulted in a more rapid onset of symptomatol-
ogy, with higher mean scores at the 30 min, 60 min, and
90 min time points. Specifically, after 30 min of pollen
exposure on Day 2, the TSS in the higher concentration
group was 12.3 (SD = 5.0)—compared to 10.1 (SD = 4.1)
on Day 1, and the TNSS reached 7.1 (SD = 2.5)—com-
pared to 5.6 (SD = 2.4) on the previous day. Earlier rises
in symptom scores were also observed in the lower
pollen concentration group on Day 2. After 30 min of
grass pollen exposure, the TSS and TNSS scores rose to
9.8 (SD = 5.6) and 5.9 (SD = 3.0) respectively on Day 2,
compared to the mean scores of 7.8 (SD = 6.0) and 4.4
(SD = 3.2) obtained the day before.
Peak nasal inspiratory flow
PNIF measurements obtained both at baseline and at
each pollen exposure time point were lower in the high
pollen concentration group than in the low concentra-
tion group. For example, after the first 3 hours of pollen
exposure, the higher concentration group reported a
mean PNIF value of 68.1 L/min (SD = 28.4), compared
to 82.4 L/min (SD = 43.6) in the lower concentration
group.
PNIF measurements dropped notably from baseline in
both pollen concentration groups after 3 hours of grass
pollen exposure. At hour 3 of their first EEU visit, the
mean PNIFs of the higher and lower concentration
groups were 29.8 L/min (relative change of 30.4%) and
42.9 L/min (34.2%) less than those reported at baseline,
respectively. Similar to TSS and TNSS, the second day
of pollen exposure did not result in very different
changes in PNIF from baseline, but resulted in a more
rapid drop in recorded PNIF measurements. After
30 min of pollen exposure, the mean PNIF fell by
22.8 L/min (26.1%) in the higher concentration group on
Day 2, compared to a 12.9 L/min (13.1%) drop on Day 1.
30 min of pollen exposure also resulted in a quicker
drop in mean PNIF in the lower concentration group,
which reported a change of 19.5 L/min (16.9%) from
baseline on Day 2 compared to a 10.3 L/min (8.2%) drop
the previous day. As well, participants in both pollen ex-
posure groups reported a lower mean baseline PNIF
measurement at the beginning of their second day of
pollen exposure than the day before.
Figure 3 Total Symptom Scores (TSS) were higher in the higher pollen concentration group (HPC) than the lower pollen concentration
group (LPC) after three hours of pollen exposure. The second day of pollen exposure in both groups resulted in similar peak TSSs after
3 hours of exposure as the day previous, but generated a more rapid increase in TSS.
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group, a significant low to moderate inverse correlation
was observed between a participant’s subjective scoring
of nasal congestion and their mean PNIF measurements.
After performing a correlative analysis as described pre-
viously, r-values for Days 1 and 2 in the high pollen con-
centration group and Days 1 and 2 in the low group
were −0.3224, −0.3457, −0.3753, and −0.3390, respect-
ively (p < 0.0001 for all). A significant positive correlationFigure 4 Total Nasal Symptom Scores (TNSS) were higher in the high
concentration group (LPC) after three hours of pollen exposure. Simil
after 3 hours of pollen exposure, however, scores increased more quickly owas also observed between reported measures of nasal
congestion TNSS scores. R-values for Days 1 and 2 in
the high pollen group and Days 1 and 2 in the low
pollen group were 0.8667, 0.8663, 0.8952, and 0.8156, re-
spectively (p < 0.0001). In addition, comparing the stand-
ard deviations of the data obtained in both the high and
low pollen concentration groups, there was no appre-
ciable difference in the variability of data between the
two days.er pollen concentration group (HPC) than the lower pollen
ar to TSS, final TNSSs on Day 2 were similar to those reported on Day 1
n Day 2.
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Exposure of timothy grass skin test positive subjects with
a clinical history of SAR symptoms during grass pollen
season (over at least 2 consecutive past seasons) to con-
trolled levels of rye grass pollen in the EEU resulted in the
development of typical symptoms of SAR in a reprodu-
cible manner. This serves as further confirmation of the
extensive clinical cross-reactivity amongst grass pollens.
Using a lower target pollen concentration of 2500 grains/
m3 corresponded with a lower mean symptom burden
compared to 3500 grains/m3. Upon return to the EEU the
following day for a subsequent 3 hour exposure to the
same target pollen concentration, maximal TSS and TNSS
responses were not appreciably higher by the 3 hour time
point, but rather these maximal responses were achieved
sooner, allowing for more predictable responses. Similarly,
changes in PNIF measurements from baseline in response
to pollen exposure were more rapid in participants from
both groups on the second day of exposure. This second
day of exposure was included to evaluate this ‘priming’ ef-
fect which has been noted previously in EEU studies [2],
whereby symptoms develop more rapidly upon subse-
quent exposures. Additionally, it served to determine
whether or not back to back exposures led to more severe
symptom scores, which did not in fact appear to be the
case.
Mean PNIF measurements obtained throughout the
duration of pollen exposure were lower in the higher
pollen concentration group, likely reflecting more severe
nasal symptoms being produced in response to the 3500
grains/m3 concentration compared to the 2500 grains/
m3 concentration. This conclusion is supported as well
by the higher TNSS and TSS responses reported by the
higher concentration group. As expected, the partici-
pant’s subjective scoring of nasal congestion correlated
well with PNIF measurements, as well as TNSS, with in-
creased congestion presumably obstructing nasal inspir-
ation and resulting in the lower PNIF values.
Participants in both pollen groups reported lower base-
line PNIF measurements on their second visit to the EEU.
This suggests that grass pollen exposure, and thus SAR
symptoms generated from the previous day, continues to
affect PNIF prior to a second exposure to grass pollen.
This result suggests a generation of a late phase response
in a proportion of the participants, and is consistent with
historically established symptom patterns of SAR.
The symptom scores generated from the group ex-
posed to 3500 grains/m3 of grass pollen generally mir-
rored the responses seen previously with our ragweed
pollen exposures, with some individuals reacting quickly
with high symptom scores and others to a lesser degree
[8]. The overall degree of symptomatic responses was
also similar to those seen in ragweed sensitive subjects
in a study conducted to evaluate the presence or absenceof late phase allergic rhinitis responses to ragweed chal-
lenge in the EEU [19]. In both of these studies, the mean
TNSS at hour 3 was 8.6 to 9.2 with standard deviations
of 2.0-2.1, respectively (8, 19, data on file). The predict-
ability of more rapid allergic symptoms achieved on the
second day of pollen exposure may help to control for
this variability, though no meaningful change in stand-
ard deviations between Day 1 and Day 2 data in the high
or low concentration groups was observed.
This study confirms that, similar to ragweed pollen,
grass pollen dispersed in the EEU can be effectively used
to elicit AR symptoms in grass-allergic individuals. Thus,
the EEU can be reliably used to study AR in grass-allergic
participants, increasing both the scope of utilization of the
unit and the pool of available participants. In addition,
such that both allergens have now been successfully vali-
dated, the difference in symptomology of ragweed and
grass-triggered AR may be discerned in patients allergic to
both allergens, as can the efficacy of interventions target-
ing each specific allergy. Other CACF have developed the
capabilities to disperse several different types of pollen, al-
though not all have published their validation work in the
searchable literature. Of note, the Biogenics Research
Chamber in San Antonio, Texas, however, recently pub-
lished a very interesting study showing the symptomatic
responses of grass allergic subjects exposed to Timothy
grass in the CACF, despite the fact that the participants
were recruited from a geographic area where Timothy
grass does not grow [20].
By examining the different responses elicited by two
different concentrations of grass pollen, the current
study has also produced a standardized framework for
subsequent grass-specific EEU trials. The higher symp-
tom burden triggered in individuals exposed to 3500
grains/m3 of pollen compared to 2500 grains/m3 would
be better suited to study the effects of the disease, as
well as provide a wider range to study the degree of
symptomatic improvement achieved by AR treatments.
Thus, we have defined 3500 grains/m3 as the optimal
grass-pollen concentration to be used as a standard for
future EEU trials by confirming its ability to produce ap-
propriate AR symptoms, the clinical validation of this
method supporting the results of future studies.Conclusions
Exposure to grass pollen in the EEU produces reliable
symptoms of allergic rhinitis in grass-sensitive patients.
The EEU can therefore be used to conduct clinical trials
evaluating grass-specific allergic interventions.
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